Jasper Therapeutics reports FY2023 net loss of $64.5M; cash runway through Q3 2025 on $50M Feb 2024 offering

Jasper Therapeutics, Inc.

Net loss for FY2023: $64.5M ($6.18 diluted EPS); Q4 net loss $16.6M ($1.50 diluted EPS).
Cash and equivalents $86.9M at Dec 31, 2023; Feb 2024 $50M offering extends runway through Q3 2025.
BEACON Phase 1b/2a in CSU enrolling; initial data from first four cohorts expected Q3 2024.
SPOTLIGHT Phase 1b/2a in CIndU approved; data expected H2 2024.
Phase 1 trial in LR-MDS initiated; initial data anticipated mid-2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jasper Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: net income $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18, EPS $6.18.

Period: fiscal year ended December 31, 2023
Net income: $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18
EPS: $6.18
Result: reported results

Exact text from the filing

Jasper reported a net loss of $16.6 million and $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $1.50 and $6.18, for the three months and the year ended December 31, 2023, respectively.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-019249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.